I(2)-Alanine, phenyl ester | 56987-03-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: I(2)-Alanine, phenyl ester
• 英文别名: phenyl 3-aminopropanoate
• CAS: 56987-03-2
• 化学式: C₉H₁₁NO₂
• mdl: MFCD09923624
• 分子量: 165.19
• InChiKey: GZFAXMFQTNLJDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] THIOPHENEDERIVATIVES FOR THE TREATMENT OF FLAVIVIRUS INFECTIONS<br/>[FR] DERIVES DE THIOPHENE POUR LE TRAITEMENT DES INFECTIONS A FLAVIVIRUS
  申请人：VIROCHEM PHARMA INC

  公开号：WO2004052879A1

  公开（公告）日：2004-06-24

  The present invention provides novel compounds represented by formula ( I): or pharmaceutically acceptable salts thereof useful for treating flaviviridae viral infection.

  本发明提供了一种 represented by formula (I) 的新化合物，或其在治疗黄病毒科病毒感染方面有用的药用盐。
• [EN] PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR<br/>[FR] PROMÉDICAMENTS DE MODULATEURS DU RÉCEPTEUR NMDA
  申请人：H LUNDBECK AS

  公开号：WO2021001420A1

  公开（公告）日：2021-01-07

  The present invention is directed to novel prodrugs of modulators of the NMDA receptor of formula I. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

  本发明涉及公式I的NMDA受体调节剂的新型前药。该发明的不同方面涉及包括上述化合物的药物组合物以及利用这些化合物治疗神经系统疾病或神经精神疾病（如抑郁症）的用途。
• OXABICYCLOHEPTANE PRODRUGS
  申请人：KOVACH JOHN S.

  公开号：US20160333024A1

  公开（公告）日：2016-11-17

  The present invention provides a compound having the structure:

  本发明提供了一种具有以下结构的化合物：
• PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL, AND COMPOSITION
  申请人：FUJIFILM Corporation

  公开号：US20180108492A1

  公开（公告）日：2018-04-19

  Provided are a photoelectric conversion element, a solar cell using the photoelectric conversion element, and a composition. The photoelectric conversion element includes a first electrode including a photosensitive layer, which includes a light absorbing agent, on a conductive support. The light absorbing agent includes a compound having a perovskite-type crystal structure that includes organic cations represented by the following Formulae (1) and (2), a cation of a metal atom, and an anion. R 1 —N(R 1a ) 3 + Formula (1) R 2 —N(R 2a ) 3 + Formula (2) In Formulae (1) and (2), R 1 represents a specific group such as an alkyl group (including a specific substituent group in a case where the number of carbons is 1 or 2), and a cycloalkyl group. R 2 represents a methyl group, an ethyl group, and the like. R 1a and R 2a represent a specific group such as a hydrogen atom and an alkyl group.

  提供了一个光电转换元件、使用该光电转换元件的太阳能电池以及一种组合物。该光电转换元件包括第一电极，该第一电极包括一个光敏层，该光敏层包括一个吸光剂，该吸光剂包括具有钙钛矿型晶体结构的化合物，其中该晶体结构包括以下式(1)和(2)所表示的有机阳离子、金属原子的阳离子和阴离子。在式(1)和(2)中，R1代表一个特定基团，如烷基基团(在碳数为1或2时包括一个特定的取代基团)和环烷基基团。R2代表甲基基团、乙基基团等。R1a和R2a代表氢原子和烷基基团等特定基团。
• CYCLIC PEPTIDE CXCR4 ANTAGONISTS
  申请人：Kohn Wayne David

  公开号：US20080300177A1

  公开（公告）日：2008-12-04

  Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.

  提供了在治疗癌症、类风湿关节炎、肺纤维化和HIV感染中有用的内酰胺环化肽CXCR4拮抗剂。